Julia Song, MD
Ophthalmology · Long Beach, CANPI 1982629010
Payments from drug & device makers
Across 584 payments — averaging $42.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$14K
- Mallinckrodt Hospital Products Inc.$2K
- Amgen$2K
- Novartis$1K
- ANI Pharmaceuticals, Inc.$961
- Bausch & Lomb, A Division Of Bausch Health US, LLC$764
- plus $4K from 23 others
What the payments were for
- Food & beverage$11,857100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 80 | $14,199 |
| Mallinckrodt Hospital Products Inc. | 100 | $2,265 |
| Amgen(2 entities) | 107 | $1,773 |
| Novartis | 62 | $1,029 |
| ANI Pharmaceuticals, Inc. | 58 | $961 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 28 | $764 |
| Bausch & Lomb Americas Inc. | 30 | $647 |
| Alcon | 31 | $603 |
| Biotissue Holdings Inc. | 9 | $355 |
| Sun Pharmaceutical Industries Inc. | 15 | $326 |
| Oyster Point Pharma, Inc. | 12 | $299 |
| Tarsus Pharmaceuticals, Inc. | 6 | $247 |
| Ellexiscience | 1 | $237 |
| Dompe US, Inc. | 9 | $219 |
| Eyevance Pharmaceuticals LLC | 11 | $189 |
| Ivantis, Inc | 1 | $154 |
| Harrow Eye, LLC | 4 | $107 |
| Glaukos Corporation | 1 | $74 |
| Aerie Pharmaceuticals, Inc. | 4 | $64 |
| Rxsight Inc | 2 | $58 |
| Akorn Operating Company LLC | 3 | $58 |
| Beaver-visitec International, Inc. | 1 | $55 |
| Kala Pharmaceuticals, Inc. | 2 | $46 |
| Shire North American Group Inc | 2 | $43 |
| Sight Sciences, Inc. | 1 | $27 |
| Boston Scientific | 1 | $26 |
| NEW World Medical,inc. | 1 | $20 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $18 |
| Akorn, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus$154
- ENVISTA TORIC$141
- VICTUS$141
- STELLARIS$141
- PURIFIED CORTROPHIN GEL$125
- MIEBO$125
- XIIDRA$125
- XDEMVY$120
How this compares
$24,874 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CortrophinCorticotropin | 11 | $750,327 |
| XiidraLifitegrast | 302 | $249,369 |
| VyzultaLatanoprostene Bunod | 200 | $94,311 |
| RestasisCyclosporine | 79 | $79,549 |
| MieboPerfluorohexyloctane/Pf | 70 | $60,597 |
| XdemvyLotilaner | 32 | $58,581 |
| Cyclosporine | 145 | $47,148 |
| LumiganBimatoprost | 111 | $46,275 |
| RocklatanNetarsudil Mesylat/Latanoprost | 96 | $46,221 |
| RhopressaNetarsudil Mesylate | 82 | $36,158 |
| ProlensaBromfenac Sodium | 81 | $28,320 |
| TyrvayaVarenicline Tartrate | 30 | $20,085 |
| Bromfenac Sodium | 61 | $14,000 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 55 | $11,438 |
| IyuzehLatanoprost/Pf | 31 | $9,612 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $647 | $404,277572 claims |
| AbbVieRestasis, Lumigan | $14,199 | $125,824190 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $64 | $82,379178 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $247 | $58,58132 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate, Besivance | $764 | $35,407114 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $299 | $20,08530 claims |
| AlconSimbrinza | $603 | $11,43855 claims |
| NovartisIlevro | $1,029 | $4,32412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Long Beach
- Julie GasperiniLong Beach$814K
- Carl HartmanLong Beach$716K
- Dan TranLong Beach$649K
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.